Shares of Acadia Pharmaceuticals ACAD lost 9.9% on Wednesday after the company announced a disappointing update from a late-stage study of its investigational candidate, intranasal carbetocin (ACP-101 ...

Acadia Pharmaceuticals (ACAD) closed the last trading session at $22.99, gaining 7.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by ...

Acadia Pharmaceuticals ACAD announced that it has signed an exclusive worldwide license agreement with Saniona, a Denmark-based clinical-stage biopharmaceutical company, to develop and commercialize ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. While you may have an investing style you rely on, finding great stocks is made ...

ACAD’s thesis centers on Nuplazid and Daybue. These are two approved and cash-generating drugs that should help ACAD fund its CNS pipeline. ACAD’s Q2 2025 revenues remain solid with Nuplazid and ...

ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) stock jumped 26.6% to $22.29 on Friday afternoon following a favorable court ruling. What To Know: The U.S. District Court for the District of Delaware upheld ...

In trading on Thursday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) crossed above their 200 day moving average of $16.68, changing hands as high as $16.82 per share. Acadia Pharmaceuticals Inc ...